Living With REMS: The New Regulatory Model Meets Commercial Reality

Amgen and GSK are competing head-to-head in a new market for a rare blood disorder. The market size is small, but the commercial implications are huge: how will the new regulatory tools imposed by FDA affect competition in the real world?